| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
This supplemental NDA for fruquintinib was based on data from the Phase III FRUTIGA study, which was declared positive due to a...
Key Takeaways: Hutchmed’s U.S. sales jumped nearly 53% in the second quarter from the previous three months, boosted by upta...
Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and raises the price target from $17 ...
HUTCHMED (China) (NASDAQ:HCM) reported quarterly earnings of $0.15 per share. This is a 84.54 percent decrease over earnings of...
HUTCHMED announced that its New Drug Application for Tazemetostat for the treatment of relapsed or refractory follicular lympho...
− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial− FRUZAQLA (fruquintinib) is the First Novel Targeted ...
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showc...
This is a Phase I, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics and efficacy of HMPL-506 in ...
